abstract |
The present invention relates to oligomeric compounds and conjugates thereof that target proprotein convertase type 9 subtilisin/Kexin (PCSK9) mRNA in cells, resulting in reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical conditions, such as hypercholesterolemia and related conditions. |